Iterum Therapeutics Plc

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Iterum Therapeutics progresses with sulopenem, faces regulatory challenges

Iterum Therapeutics (ITRM) showcased progress in key areas like FDA interactions, patent approvals, and maintaining a strong financial position.
While challenges exist in regulatory approval and funding, the company's strategic vision and commitment to growth offer opportunities for success.
Overall, Iterum's focus on advancing sulopenem for uncomplicated UTIs and engaging with the FDA reflects a promising trajectory for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Activision Blizzard

Katapult Holdings

NEW YORK, NY / ACCESSWIRE / October 3, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATVI, ITRM and KPLT

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Iterum Therapeutics plc ("Iterum" or the "Company") (NASDAQ: ITRM) and certain of its officers. The class action, filed in the United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 21-cv-04181, is on behalf of a class consisting of all persons and entities other than...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Iterum Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - ITRM

Boston Beer Company

SelectQuote

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for ITRM, SLQT and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Iterum Therapeutics plc ("Iterum" or "the Company") (NASDAQ: ITRM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Iterum securities between November 30, 2020 and July 23, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.

Monday Deadline for Investors to Actively Participate in Iterum Therapeutics plc (ITRM) Class Action - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / September 30, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ITRM, SLQT and SAM

Acurx Pharmaceuticals LLC

Cidara Therapeutics

Melinta Therapeutics

Nabriva Therapeutics

Paratek Pharma

SCYNEXIS

Summit Therapeutics

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021.

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

San Diego, California--(Newsfile Corp. - September 29, 2021) -  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Iterum Therapeutics plc (NASDAQ: ITRM) securities between November 30, 2020 and July 23, 2021, inclusive ("Class Period") have until this upcoming Monday, October 4, 2021 to seek appointment as lead plaintiff in the Iterum class action lawsuit. The Iterum class action lawsuit charges Iterum and certain of its top executives with violations of...

ITRM MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Iterum Therapeutics plc Class Action Lawsuit

The stock price of Iterum Therapeutics PLC (NASDAQ: ITRM) increased by over 25% pre-market today. This is why it happened.

ITRM Stock: Why It Substantially Increased Today

Yamana Gold

NovaBay Pharmaceuticals

Are these penny stocks worth adding to your October watchlist? The post Why These Penny Stocks Deserve a Spot On Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why These Penny Stocks Deserve a Spot On Your Watchlist Right Now

Los Angeles, California--(Newsfile Corp. - September 28, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iterum Therapeutics plc ("Iterum" or "the Company") (NASDAQ: ITRM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 30, 2020 and July 23, 2021, inclusive...

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Iterum Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 28, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021, inclusive (the "Class Period"), of the important October 4, 2021 lead plaintiff deadline.SO WHAT: If you purchased Iterum securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - ITRM

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTI).

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021.

Iterum Therapeutics to Present Data at IDWeek 2021

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Iterum Therapeutics plc ("Iterum" or the "Company") (NASDAQ: ITRM) from November 30, 2020 through July 23, 2021 (the "Class Period").

ITERUM THERAPEUTICS PLC (NASDAQ: ITRM) OCTOBER 4, 2021 INVESTOR FILING DEADLINE:

NEW YORK, Sept. 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021, inclusive (the "Class Period"), of the important October 4, 2021 lead plaintiff deadline.

ROSEN, A TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - ITRM

AdaptHealth Corp

NEW YORK, NY / ACCESSWIRE / September 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: AHCO ITRM KPLT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

SAN DIEGO, Sept. 25, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Iterum Therapeutics plc (NASDAQ: ITRM) securities between November 30, 2020 and July 23, 2021, inclusive ("Class Period") have until October 4, 2021 to seek appointment as lead plaintiff.

ITRM UPCOMING DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Iterum Therapeutics plc Class Action Lawsuit

Royal Philips

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATVI, ITRM and PHG

New York, New York--(Newsfile Corp. - September 24, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Iterum Therapeutics plc ("Iterum" or the "Company") (NASDAQ: ITRM) from November 30, 2020 through July 23, 2021 (the "Class Period"). The lawsuit filed in...

ITERUM THERAPEUTICS PLC (ITRM) SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Iterum Therapeutics plc

New York, New York--(Newsfile Corp. - September 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021, inclusive (the "Class Period"), of the important October 4, 2021 lead plaintiff deadline.SO WHAT: If you purchased Iterum securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Rosen, Top Ranked Investor Counsel, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - ITRM

View

Yalla Group

NEW YORK, NY / ACCESSWIRE / September 21, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ITRM, YALA and VIEW

CorMedix

NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, ITRM and PHG

Spectrum Pharma

NEW YORK, NY / ACCESSWIRE / September 17, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for ITRM, SLQT and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ATI Physical Therapy

Cassava Sciences Inc

NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: ITRM ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021, inclusive (the "Class Period"), of the important October 4, 2021 lead plaintiff deadline.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Iterum Therapeutics plc Investors with Losses Exceeding $100K to Secure Counsel Before Important October 4 Deadline in Securities Class Action - ITRM

News for Iterum Therapeutics Plc Stock (ITRM)